SELLAS Life Sciences Group, Inc.
SLS$700M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaNEW YORK
Drugs in Pipeline
6
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Dec 30, 2026
41wMarket Overview
Stock performance and key metrics
SLS News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
Galinpepimut-S
Acute Myeloid Leukemia
Decitabine
Acute Myeloid Leukemia
pembrolizumab
Acute Myelogenous Leukemia
Galinpepimut-S + Montanide + GM-CSF
Malignant Pleural Mesothelioma
lenalidomide
Multiple Myeloma
SLS009
Hematologic Malignancies
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Galinpepimut-S | Phase 3 | Acute Myeloid Leukemia | - | - |
Decitabine | Phase 3 | Acute Myeloid Leukemia | - | - |
pembrolizumab | Phase 2 | Acute Myelogenous Leukemia | - | - |
Galinpepimut-S + Montanide + GM-CSF | Phase 2 | Malignant Pleural Mesothelioma | - | - |
lenalidomide | Phase 2 | Multiple Myeloma | - | - |
SLS009 | Phase 2 | Hematologic Malignancies | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply